Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Jesse M.
Jesse M. Attas, Austin, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20090288073 | Edit Time Analyzer in a Loosely Typed Textual Language - Analyzing code written in a loosely typed language. User input specifying code for a script may be received. The specified code may be analyzed. More specifically, one or more code portions referenced by the specified code may be determined. Properties of symbols of the specified code and the one or more code portions may also be determined. Additionally, the specified code may be analyzed using the determined properties to determine errors in the specified code. Accordingly, one or more errors may be graphically indicated based on said analyzing. Receiving the user input, analyzing the specified code, and graphically indicating the one or more errors may be performed at edit time. | 11-19-2009 |
Jesse M. Cedarbaum, San Francisco, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20100152305 | METHODS OF TREATMENT OF HYPERURICEMIA AND ASSOCIATED DISEASE STATES - The present disclosure relates to compositions and methods for reducing uric acid levels in a individual in need thereof. The present disclosure further relates to the treatment of hyperuricemia and diseases associated with high uric acid levels in mammals using scyllo-inositol. | 06-17-2010 |
Jesse M. Cedarbaum, Larchmont, NY US
| Patent application number | Description | Published |
|---|---|---|
| 20080214465 | Method of administering and using VEGF inhibitors for the treatment of human cancer - A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF). | 09-04-2008 |
| 20080214466 | Method of administering and using VEGF inhibitors for the treatment of human cancer - A method of treating a human patient suffering from cancer, comprising administering an effective amount of a vascular endothelial growth factor (VEGF) trap antagonist to the human patient, the method comprising: (a) administering to the patient an initial dose of at least approximately 0.3 mg/kg of the VEGF antagonist; and (b) administering to the patient a plurality of subsequent doses of the VEGF antagonist in an amount that is approximately the same or less of the initial dose, wherein the subsequent doses are separated in time from each other by at least one day. The methods of the invention are useful for treating a human cancer selected from the group consisting of renal cell carcinoma, pancreatic carcinoma, breast cancer, prostate cancer, colorectal cancer, malignant mesothelioma, multiple myeloma, ovarian cancer, and melanoma. The invention is further useful for treating a condition which benefits from the reduction of VEGFA and placental growth factor (PLGF). | 09-04-2008 |
| 20090285841 | ANTITUMOR COMBINATIONS CONTAINING A VEGF-INHIBITING AGENT AND 5FU OR A DERIVATIVE THEREOF - This invention relates to antitumor combinations comprising a VEGF inhibitor combined with 5-fluorouracil or with a 5-fluoropyrimidine derivative that are therapeutically useful in the treatment of neoplastic diseases, and pharmaceutical compositions comprising such combinations. | 11-19-2009 |
Jesse M. Klostranec, Toronto CA
| Patent application number | Description | Published |
|---|---|---|
| 20100151443 | MICROFLUID SYSTEM AND METHOD TO TEST FOR TARGET MOLECULES IN A BIOLOGICAL SAMPLE - A system and method to test for the presence of target molecules in a biological test sample includes test molecules, a microfluidic chip, and irradiating and detection devices. The test molecules include bio-recognition molecules conjugable with the target molecules, and the corresponding conjugates. The microfluidic chip includes sample channels and flow focusing channels adjoining the sample channels. A buffer exiting from the focusing channels directs a single-file stream of the test molecules through one of the sample channels. The irradiating device delivers radiation for absorption by the test molecules in the single-file stream. After absorption, the test molecules emit fluorescence of a distinct fluorescent spectrum for each of the conjugates. The detection device monitors identifies the presence of the conjugates by monitoring for the distinct fluorescent spectrum. Thus, the test system and method identifies the presence of the target molecules in the test sample. | 06-17-2010 |
| 20110053278 | SYSTEMS AND METHODS FOR ENHANCING FLUORESCENT DETECTION OF TARGET MOLECULES IN A TEST SAMPLE - Systems and methods for enhancing fluorescent detection of target molecules in a test sample are for use with an irradiating device. First fluorophores are provided for absorption of EMF radiation, and emission of a first signal. Second fluorophores are provided for partial absorption of the first signal, and emission of a second signal distinguishable from the first signal. The fluorophores are combined with the test sample, and secured to the target molecules and relative to one another. After the first fluorophores receive the EMF radiation from the irradiating device, the first signal is detected, together with the second spectral signal if the target molecules are present in the test sample. | 03-03-2011 |
Jesse M. Marzullo, Meriden, CT US
| Patent application number | Description | Published |
|---|---|---|
| 20110104582 | TAILORING LIQUID WATER PERMEABILITY OF DIFFUSION LAYERS IN FUEL CELL STACKS - A fuel cell stack ( | 05-05-2011 |